Experienced in Menorrhagia

Dr. James F. Barter

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
6301 Executive Blvd, 
Rockville, MD 
Accepting New Patients
Experienced in Menorrhagia
6301 Executive Blvd, 
Rockville, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Barter is a Gynecologic Oncologist and an Oncologist in Rockville, Maryland. Dr. Barter is rated as an Experienced provider by MediFind in the treatment of Menorrhagia. His top areas of expertise are Ovarian Cysts, Neonatal Ovarian Cyst, Endometrial Cancer, Hysterectomy, and Oophorectomy. Dr. Barter is currently accepting new patients.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

6301 Executive Blvd, Rockville, MD 20852

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Patients With Platinum-Resistant Ovarian Cancer (MOONSTONE)
Enrollment Status: Terminated
Publish Date: September 10, 2022
Intervention Type: Drug
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

5 Total Publications

Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 24, 2024
Similar Doctors
Distinguished in Menorrhagia
Dr. James A. Simon
Obstetrics and Gynecology | Reproductive Medicine
Distinguished in Menorrhagia
Dr. James A. Simon
Obstetrics and Gynecology | Reproductive Medicine
1850 M St Nw, 
Washington, DC 
 (10.8 miles away)
Languages Spoken:
English
See accepted insurances

James Simon is an Obstetrics and Gynecologist and a Reproductive Medicine provider in Washington, Washington, D.c.. Dr. Simon is rated as a Distinguished provider by MediFind in the treatment of Menorrhagia. His top areas of expertise are Menopause, Menorrhagia, Uterine Fibroids, Hormone Replacement Therapy (HRT), and Hysterectomy.

Distinguished in Menorrhagia
Dr. Adegboyega I. Adejana
Obstetrics and Gynecology
Distinguished in Menorrhagia
Dr. Adegboyega I. Adejana
Obstetrics and Gynecology
1414 Crain Hwy N, Suite 1a, 
Glen Burnie, MD 
 (29.0 miles away)
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients

Adegboyega Adejana is an Obstetrics and Gynecologist in Glen Burnie, Maryland. Dr. Adejana is rated as an Advanced provider by MediFind in the treatment of Menorrhagia. His top areas of expertise are Menorrhagia, Amenorrhea, Pelvic Inflammatory Disease, Hormone Replacement Therapy (HRT), and Intrauterine Device Insertion. Dr. Adejana is currently accepting new patients.

Distinguished in Menorrhagia
Dr. Aryian L. Cooke
Obstetrics and Gynecology
Distinguished in Menorrhagia
Dr. Aryian L. Cooke
Obstetrics and Gynecology
7651 Matapeake Business Dr, Suite 204, 
Brandywine, MD 
 (29.2 miles away)
240-252-2140
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Aryian Cooke is an Obstetrics and Gynecologist in Brandywine, Maryland. Dr. Cooke is rated as a Distinguished provider by MediFind in the treatment of Menorrhagia. Her top areas of expertise are Vulvovaginitis, Female Genital Sores, Pelvic Inflammatory Disease, Hydrocele, and Intrauterine Device Insertion. Dr. Cooke is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barter's expertise for a condition
ConditionClose
    View All 12 Distinguished Conditions
    View All 10 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile